Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

KP104

KP104 will be administered.